Borami Kim
About Borami Kim
Borami Kim is a Market Access Manager at Bristol Myers Squibb in Seoul, South Korea, with extensive experience in the pharmaceutical industry and a strong background in health economics.
Company: Bristol Myers Squibb
Borami Kim is currently employed at Bristol Myers Squibb as a Market Access Manager. The company's focus on innovative medicine benefits from her extensive experience in market access, oncology marketing, and health outcomes. Based in Seoul, South Korea, she works on market access strategies that aim to enhance patient access to new treatments.
Title: Market Access Manager
As a Market Access Manager, Borami Kim is responsible for developing and implementing strategies that improve market access for pharmaceutical products. Her role involves ensuring that patients can obtain necessary medications through efficient pricing and reimbursement frameworks. Kim utilizes her extensive expertise in health economics, pricing, and reimbursement to navigate complex market dynamics.
Education and Expertise: Seoul National University
Borami Kim has a distinguished academic background, with a Doctor of Philosophy (Ph.D.)-candidate and a Master of Public Health (MPH) in Health Economics from Seoul National University's Graduate School of Public Health. Her comprehensive education in health economics and public health administration has equipped her with the analytical skills and theoretical knowledge needed for her roles in the pharmaceutical industry.
Background: Professional Experience
Borami Kim has held various roles in the pharmaceutical industry, contributing to multinational companies such as Eli Lilly, Mundipharma Korea, and CMIC-VPS. Her positions ranged from Oncology Marketing Lead to Pricing Reimbursement and Access Specialist. Each role enhanced her experience in clinical trials, statistical analysis, and strategic health outcomes, providing her with the necessary skills to excel in market access management.
Achievements: Clinical Trials and Market Access Projects
Borami Kim has made significant contributions through managing large databases for clinical trials and post-marketing surveillance surveys. She has authored Clinical Study Reports for the Korea Ministry of Food and Drug Safety and led Pricing, Reimbursement, and Market Access projects for new drugs. Her efforts have consistently contributed to improving access to innovative pharmaceuticals and advancing health outcomes through strategic dissemination of scientific information.